Linked Life Data

21053108

Source:http://linkedlifedata.com/resource/pubmed/id/21053108

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2011-1-4
pubmed:abstractText
Knowledge of estrogen receptor (ER), progesterone receptor (PgR) and human epidermal growth factor receptor-2 (HER2) status is necessary for determining the optimal treatment of breast cancer patients. At the same time, the discordance between marker profiles (ER/PR and HER2) of primary and metastatic breast cancer is well documented. Whether discordant cases are secondary to "clonal selection" in the face of targeted anti-estrogen or anti-HER2 therapy or whether they are a laboratory artifact is still debated; both scenarios are likely. This article outlines current modalities for ER, PR, and HER2 testing in primary breast carcinoma and its metastases and reviews prospective and retrospective studies that have addressed these issues, as well as recent advances in the field.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1534-6269
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
13
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
17-25
pubmed:meshHeading
pubmed:year
2011
pubmed:articleTitle
The need to examine metastatic tissue at the time of progression of breast cancer: is re-biopsy a necessity or a luxury?
pubmed:affiliation
Evelyn H. Lauder Breast and Imaging Center, Memorial Sloan-Kettering Cancer Center, 300 East 66th Street, New York, NY 10065, USA. mkhasraw@med.usyd.edu.au
pubmed:publicationType
Journal Article, Review